A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Active Not Recruiting. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 3
- Study design
- RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE
- Evidence population
- Human clinical study registration
- Participants
- 735
- Population
- ALL · 50 Years to 89 Years
- Duration
- 2022-01-13 to 2027-11-01
- Intervention
- ABBV-RGX-314 Dose 1; ABBV-RGX-314 Dose 2; Aflibercept (EYLEA®)
- Comparator
- Control Arm
- Outcomes measured
- Mean change from baseline in Best Corrected Visual Acuity (BCVA) — At Week 54; Bilateral Treatment Substudy: Incidence of ocular AEs and any SAEs — Week 50; Incidences of ocular and overall AEs — Through Week 54; Proportion of participants with improved BCVA — Week 54; Proportion of participants with worsened BCVA — Week 54; Proportion of participants (1) gaining or losing greater than 0 letters; (2) maintaining vision compared with baseline…; Mean change from baseline in BCVA for participants who received 0 or more supplemental anti-VEGF injection (ABBV-RGX- 3…; Mean change from Week 54 to Week 108 in BCVA (control arm participants who cross over to ABBV-RGX-314) — Week 54 to Wee…; Mean change in central retinal thickness (CRT) as measured by SD-OCT — Through Week 108; Mean change in central point thickness (CPT) as measured by SD-OCT — Through Week 108; Mean number of supplemental anti-VEGF injections from Baseline through Week 54 (ABBV-RGX-314 randomized participants) a…; Proportion of participants with 0, 1, 2, and 3 supplemental injections through Week 54 (ABBV-RGX-314 randomized partici…; Proportion of participants with ≤ 1, ≤ 2, and ≤ 3 supplemental injections through Week 54 (ABBV-RGX-314 randomized part…; Proportion of participants that received 1 or 2 injections through Week 54 (ABBV-RGX-314 randomized participants) and f…; Proportion of participants with a reduction of ≥ 50% in anti-VEGF injection annualized rate through Week 54 compared wi…; Proportion of participants with a reduction of ≥ 75% in anti-VEGF injection annualized rate through Week 54 compared wi…; Percent reduction in anti-VEGF injection annualized rate through Week 54 compared with the prior year (ABBV-RGX-314 ran…; Supplemental anti-VEGF injection annualized rate through Week 54 (ABBV-RGX-314 randomized participants) — Through Week…; Percent reduction in anti-VEGF injection annualized rate after Week 58 through Week 108 relative to the year prior to s…; Supplemental anti-VEGF injection annualized rate after Week 58 through Week 108 (control arm participants who cross ove…
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Vision ageing · 100%Abstract contains controlled term: age-related macular degeneration. Source terminology contains: age-related macular degeneration. Abstract supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.
Automated source check 100% · update recency 100%. These figures help sort records; they are not medical ratings.